Overview
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) developed to stimulate pulsatile endogenous growth hormone release rather than directly administering growth hormone. The FDA first approved tesamorelin in 2010 for reducing excess abdominal fat in adults with HIV-associated lipodystrophy, and newer Egrifta formulations remain prescription-only products. Its role is narrow but real: clinical trials showed reductions in visceral adipose tissue in a specific HIV population with central fat accumulation.
Mechanistically, tesamorelin binds GHRH receptors in the anterior pituitary, increasing growth hormone secretion and downstream insulin-like growth factor 1 (IGF-1). That endocrine signal shifts lipid metabolism and preferentially reduces visceral fat in studied populations. It is not a generic weight-loss peptide, and the prescribing information specifically notes it is not indicated for weight-loss management. Users often discuss it for body composition, but the strongest evidence is still HIV-associated visceral adiposity.
Tesamorelin is FDA-approved, but that does not make it casual or low-risk. It can raise IGF-1, affect glucose handling, cause injection-site reactions, fluid retention, arthralgia, and hypersensitivity reactions, and it is contraindicated in active malignancy, pregnancy, and disruption of the hypothalamic-pituitary axis. Long-term cardiovascular outcome data are not established. Treatment effects may reverse after discontinuation, so it should be viewed as maintenance therapy when used for its approved indication.
This guide focuses on tesamorelin's evidence-backed role, practical mechanism, pharmacokinetics from prescribing information, safety screening, and key differences between prescription tesamorelin and research-market products. The practical message is simple: tesamorelin has much stronger human data than most peptide-clinic compounds, but its validated indication is specific, and off-label body-composition use needs medical supervision and realistic expectations.
Quick facts
- Mechanism
- Pituitary GHRH receptor agonist that raises GH and IGF-1
- Primary use
- HIV-associated visceral fat reduction
- Evidence
- strong
- FDA
- Approved
- Route
- Subcutaneous injection
- Typical results
- Visceral fat reduction over 26 weeks in HIV lipodystrophy trials
Chemical information
Tesamorelin is a 44-amino-acid GHRH analog with a molecular mass of 5,135.91 g/mol and the formula C221H366N72O67S. Its N-terminal modification improves stability compared with native GHRH while preserving pituitary GHRH receptor activity.
How Tesamorelin works
Tesamorelin activates GHRH receptors on pituitary somatotrophs, increasing endogenous growth hormone secretion in a more physiologic pattern than exogenous GH injections. Growth hormone then promotes hepatic and peripheral IGF-1 production and alters lipid metabolism, with clinical trials showing preferential reductions in visceral adipose tissue. The mechanism is endocrine and systemic, so monitoring matters: IGF-1, glucose, cancer history, fluid retention symptoms, and injection reactions are central safety considerations.
In HIV-associated lipodystrophy, visceral fat accumulation may coexist with altered growth hormone secretion, insulin resistance, dyslipidemia, and antiretroviral exposure. Tesamorelin attempts to correct one part of that system by stimulating GHRH signaling and increasing GH pulsatility. In trials, this translated into measurable CT-based VAT reduction without a comparable intended loss of subcutaneous fat, which is clinically relevant because many patients with HIV lipodystrophy already have peripheral lipoatrophy.
The downstream IGF-1 rise is both part of the desired pharmacology and a safety issue. IGF-1 mediates many anabolic and metabolic GH effects, but sustained elevations raise concern in patients with active malignancy or high cancer risk. Prescribing information recommends IGF-1 monitoring and careful risk assessment. This is why tesamorelin should not be treated like a simple fat-loss supplement; it changes endocrine signaling in a way that can be measured and can matter clinically.
Tesamorelin has also been studied for liver fat and inflammatory markers in people with HIV and abdominal fat accumulation. A JAMA randomized trial reported reductions in visceral and liver fat over 6 months, while other analyses linked visceral fat reduction with selected metabolic changes. These findings are promising but still population-specific. They do not prove that tesamorelin is appropriate for non-HIV obesity, bodybuilding, or general longevity protocols.
- GHRH agonism: Stimulates pituitary growth hormone release through GHRH receptor activation
- IGF-1 signaling: Raises IGF-1, which mediates many metabolic and anabolic downstream effects
- VAT selectivity: Clinical trials showed preferential visceral fat reduction in HIV lipodystrophy
- Not general weight loss: FDA labeling states it is not indicated for weight-loss management
- Endocrine monitoring: IGF-1, glucose, edema, arthralgia, and cancer history are clinically important
- Reversibility: Visceral fat may reaccumulate after stopping therapy
Pharmacokinetics
Tesamorelin has human pharmacokinetic information in prescribing documents, but formulation matters. Research-market vials may not match FDA-approved Egrifta formulations, so label data should not be automatically applied to unverified products.
| Parameter | Value | Significance |
|---|---|---|
| Route | Subcutaneous injection | Approved route for Egrifta products |
| Approved indication | HIV-associated lipodystrophy VAT reduction | Evidence is strongest in this population |
| Dose in trials/labeling | Daily subcutaneous administration | Prescription dosing depends on formulation and label |
| Primary biomarker | IGF-1 increase | Used to reflect GH-axis activation and safety monitoring |
| Treatment duration studied | 26-52 weeks in pivotal studies | VAT reduction was evaluated over months, not days |
| Discontinuation effect | VAT can return after stopping | Benefits may require continued therapy |
Dosing & administration
FDA-approved tesamorelin is used as a prescription subcutaneous injection for adults with HIV-associated lipodystrophy. Current product labeling should be followed because available formulations differ; users should not extrapolate dosing from older products, clinic handouts, or research vials.
Clinical trials generally evaluated daily subcutaneous administration over 26 weeks, with some extension data to 52 weeks. Monitoring commonly includes waist measures or imaging-based VAT assessment in research, IGF-1, glucose status, injection reactions, edema, joint symptoms, and review of malignancy history.
Off-label use for general fat loss, bodybuilding, or non-HIV metabolic health is not the FDA-approved use and has much weaker evidence. Because tesamorelin changes the GH/IGF-1 axis, dose changes and continuation decisions should be made with a clinician rather than by subjective body-composition goals alone.
Side effects & safety
Tesamorelin has meaningful human safety data, but it is not risk-free. Contraindications and monitoring around malignancy, pregnancy, pituitary-axis disruption, IGF-1 elevation, glucose intolerance, hypersensitivity, and fluid-retention symptoms are central to responsible use.
Common
- • Injection-site redness, itching, or pain
- • Joint pain or stiffness
- • Muscle aches
- • Peripheral swelling or fluid retention
- • Headache
- • Mild glucose increases
Serious / potential risks
- • Hypersensitivity reactions
- • Elevated IGF-1 requiring discontinuation or reassessment
- • Worsening glucose intolerance or diabetes control
- • Contraindicated use in active malignancy
- • Pregnancy-related fetal risk
Drug interactions
Tesamorelin interaction concerns are mainly endocrine and metabolic rather than classic CYP-mediated interactions.
| Medication | Interaction | Recommendation |
|---|---|---|
| Insulin or sulfonylureas | Tesamorelin may affect glucose control | Monitor glucose and adjust diabetes therapy clinically |
| Oral glucocorticoids | May blunt growth hormone effects and worsen glucose control | Use only with clinician oversight |
| Growth hormone or IGF-1 products | Additive GH/IGF-1 axis stimulation | Avoid unsupervised combination |
| Antiretroviral therapy | Studied in people receiving ART, but HIV regimen review is needed | Coordinate with HIV clinician |
| Cancer therapies | GH/IGF-1 signaling may be inappropriate in active malignancy | Contraindicated in active malignancy; specialist input required |
Storage & handling
Lyophilized (powder)
- • Store at -20°C to 4°C (freezer or refrigerator)
- • Protect from light and moisture
- • Stable for 12–24 months when stored properly
- • Keep in original sealed container until reconstitution
Reconstituted solution
- • Refrigerate at 2–8°C after reconstitution
- • Use bacteriostatic water for multi-dose reconstitution
- • Typical stability: 14–28 days refrigerated
- • Do not freeze reconstituted solution
Cost & availability
| Source | Cost | Notes |
|---|---|---|
| FDA-approved prescription product | Often several thousand dollars per month before coverage | Insurance coverage depends on indication and prior authorization |
| Specialty pharmacy | Plan-dependent copay | Preferred for verified product handling and patient support |
| Research peptide market | $100-$300+ per vial | Not equivalent to approved Egrifta products; purity and formulation are uncertain |
| Clinical monitoring | Clinic- and lab-dependent | IGF-1 and glucose monitoring add real cost |
The bottom line
Tesamorelin is one of the few peptide drugs with strong human evidence and FDA approval, but its approved role is narrow: reducing excess abdominal visceral fat in adults with HIV-associated lipodystrophy. It is not a casual weight-loss peptide, and GH/IGF-1-axis monitoring is essential.
Best for
- • Adults with HIV-associated lipodystrophy under specialist care
- • Research on GH-axis modulation and visceral fat
- • Patients who can monitor IGF-1 and glucose
- • Clinician-guided use of verified prescription product
Not for
- • General cosmetic weight loss
- • Active malignancy
- • Pregnancy
- • Unsupervised stacking with GH secretagogues or growth hormone
Related compounds
Svetinorm
Related entry from the same enrichment batch for comparison of evidence, handling, and user-safety context.
Taxorest
Related entry from the same enrichment batch for comparison of evidence, handling, and user-safety context.
Testagen
Related entry from the same enrichment batch for comparison of evidence, handling, and user-safety context.
Testoluten
Related entry from the same enrichment batch for comparison of evidence, handling, and user-safety context.
Frequently asked questions
References
- [1] Spooner LM, Olin JL. Tesamorelin: A Growth Hormone-Releasing Factor Analogue for HIV-Associated Lipodystrophy. Annals of Pharmacotherapy (2012). doi: 10.1345/aph.1Q629 PMID: 22298602
- [2] Dhillon S. Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy. Drugs (2011). doi: 10.2165/11202240-000000000-00000 PMID: 21668043
- [3] Allas S, Kotler D, Grinspoon S, et al.. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS (2008). doi: 10.1097/QAD.0b013e32830a5058 PMID: 18690162
- [4] Falutz J, Potvin D, Mamputu JC, et al.. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. Journal of Acquired Immune Deficiency Syndromes (2010). doi: 10.1097/QAI.0b013e3181cbdaff PMID: 20101189
- [5] Stanley TL, Feldpausch MN, Oh J, et al.. Effect of Tesamorelin on Liver Fat and Visceral Fat in HIV-Infected Patients With Abdominal Fat Accumulation: A Randomized Clinical Trial. JAMA (2014). doi: 10.1001/jama.2014.8334 PMID: 25038357
- [6] Theratechnologies Inc.. EGRIFTA WR (tesamorelin) prescribing information. US Food and Drug Administration Label (2025).